CL2015001803A1 - Composición inmunogénica que comprende cepas del virus del oeste del nilo muerto o inactivado o cualquier antígeno del mismo; y método para disminuir síntomas clínicos asociados a infección por dicho virus en animales (div. sol. n° 445-11) - Google Patents
Composición inmunogénica que comprende cepas del virus del oeste del nilo muerto o inactivado o cualquier antígeno del mismo; y método para disminuir síntomas clínicos asociados a infección por dicho virus en animales (div. sol. n° 445-11)Info
- Publication number
- CL2015001803A1 CL2015001803A1 CL2015001803A CL2015001803A CL2015001803A1 CL 2015001803 A1 CL2015001803 A1 CL 2015001803A1 CL 2015001803 A CL2015001803 A CL 2015001803A CL 2015001803 A CL2015001803 A CL 2015001803A CL 2015001803 A1 CL2015001803 A1 CL 2015001803A1
- Authority
- CL
- Chile
- Prior art keywords
- west
- virus
- div
- sol
- antigen
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 241000710886 West Nile virus Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/193—Equine encephalomyelitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9308108P | 2008-08-29 | 2008-08-29 | |
US11708608P | 2008-11-21 | 2008-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015001803A1 true CL2015001803A1 (es) | 2015-10-16 |
Family
ID=41280460
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000445A CL2011000445A1 (es) | 2008-08-29 | 2011-02-28 | Composicion inmunogenica que comprende una o mas cepas del virus del oeste del nilo muerto o inactivado o cualquier antigeno del mismo; metodo para disminuir la incidencia o disminuir la severidad de los sintomas clinicos asociados con o causados por el virus del oeste del nilo en un animal. |
CL2015001803A CL2015001803A1 (es) | 2008-08-29 | 2015-06-22 | Composición inmunogénica que comprende cepas del virus del oeste del nilo muerto o inactivado o cualquier antígeno del mismo; y método para disminuir síntomas clínicos asociados a infección por dicho virus en animales (div. sol. n° 445-11) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000445A CL2011000445A1 (es) | 2008-08-29 | 2011-02-28 | Composicion inmunogenica que comprende una o mas cepas del virus del oeste del nilo muerto o inactivado o cualquier antigeno del mismo; metodo para disminuir la incidencia o disminuir la severidad de los sintomas clinicos asociados con o causados por el virus del oeste del nilo en un animal. |
Country Status (14)
Country | Link |
---|---|
US (3) | US8821889B2 (es) |
EP (1) | EP2334327B1 (es) |
JP (2) | JP5713454B2 (es) |
KR (1) | KR101813017B1 (es) |
CN (1) | CN102348466B (es) |
AU (1) | AU2009287449B2 (es) |
BR (1) | BRPI0918897B1 (es) |
CA (1) | CA2735164C (es) |
CL (2) | CL2011000445A1 (es) |
CO (1) | CO6331444A2 (es) |
MX (1) | MX2011002071A (es) |
NZ (2) | NZ591188A (es) |
SG (1) | SG193821A1 (es) |
WO (1) | WO2010025469A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011002071A (es) | 2008-08-29 | 2011-04-05 | Boehringer Ingelheim Vetmed | Vacuna para el virus del nilo occidental. |
BR122019023542B1 (pt) | 2011-03-14 | 2022-02-15 | Boehringer Ingelheim Vetmedica, Inc | Composição imunogênica compreendendo uma ou mais cepas de vírus da rinite equina b (erbv) inativado e seu método de preparação |
BR112013033522A8 (pt) | 2011-06-27 | 2018-03-13 | Intervet Int Bv | composição aquosa, composição injetável, polímero de ácido acrílico, e, uso de um polímero de ácido acrílico |
CN108601825B (zh) * | 2015-07-16 | 2023-06-20 | 巴拉特生物技术国际有限公司 | 疫苗组合物 |
WO2018176075A1 (en) * | 2017-03-27 | 2018-10-04 | The University Of Queensland | Chimeric insect-specific flaviviruses |
CA3084042A1 (en) * | 2017-12-04 | 2019-06-13 | Intervet International B.V. | Vaccination with replicon particles and oil adjuvant |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2702373B1 (fr) * | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
KR20030036189A (ko) * | 2000-05-26 | 2003-05-09 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
CA2438692C (en) | 2001-02-28 | 2010-04-27 | Akzo Nobel Nv | Injectable water-in-oil emulsions |
WO2002072036A2 (en) * | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
US20030104008A1 (en) * | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
PL212212B1 (pl) * | 2001-07-27 | 2012-08-31 | Wyeth Corp | Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania |
DK1441761T3 (da) * | 2001-10-19 | 2007-08-27 | Acambis Inc | Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr |
MXPA05005140A (es) * | 2002-11-15 | 2005-08-19 | Acambis Inc | Vacuna contra el virus del nilo occidental. |
CA2432738A1 (en) * | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
JP2007068401A (ja) | 2003-08-07 | 2007-03-22 | Chemo Sero Therapeut Res Inst | 西ナイルウイルスワクチン |
US7585621B2 (en) * | 2003-09-09 | 2009-09-08 | Idexx Laboratories, Inc. | Detection of West Nile virus infection and vaccination |
US7459163B2 (en) * | 2004-02-25 | 2008-12-02 | University Of Kansas | Infectious DNA as a vaccine against west nile and other flaviviruses |
EP1773403B1 (en) * | 2004-07-09 | 2018-04-25 | The University of North Carolina At Chapel Hill | Alphavirus-based adjuvants |
US7482017B2 (en) * | 2004-09-09 | 2009-01-27 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
EP1645283A1 (en) * | 2004-10-08 | 2006-04-12 | Chiron Behring GmbH & Co. KG | Combination vaccine |
AU2005318171B2 (en) * | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
NZ564375A (en) * | 2005-06-24 | 2010-02-26 | Intervet Int Bv | Inactivated chimeric flavivirus vaccines and related methods of use |
NZ567684A (en) | 2005-11-01 | 2011-06-30 | Intervet Int Bv | Prime boost vaccine for the protection of equines against equine influenza |
US7455842B2 (en) * | 2005-12-05 | 2008-11-25 | University Of Kansas | Chimeric West Nile viruses and uses thereof |
MX2011002071A (es) * | 2008-08-29 | 2011-04-05 | Boehringer Ingelheim Vetmed | Vacuna para el virus del nilo occidental. |
-
2009
- 2009-08-31 MX MX2011002071A patent/MX2011002071A/es active IP Right Grant
- 2009-08-31 US US12/937,504 patent/US8821889B2/en active Active
- 2009-08-31 CN CN200980143202.9A patent/CN102348466B/zh active Active
- 2009-08-31 JP JP2011525279A patent/JP5713454B2/ja active Active
- 2009-08-31 NZ NZ591188A patent/NZ591188A/xx not_active Application Discontinuation
- 2009-08-31 EP EP09792117.5A patent/EP2334327B1/en active Active
- 2009-08-31 NZ NZ60385409A patent/NZ603854A/en active IP Right Revival
- 2009-08-31 CA CA2735164A patent/CA2735164C/en active Active
- 2009-08-31 BR BRPI0918897-5A patent/BRPI0918897B1/pt active IP Right Grant
- 2009-08-31 SG SG2013064332A patent/SG193821A1/en unknown
- 2009-08-31 AU AU2009287449A patent/AU2009287449B2/en active Active
- 2009-08-31 WO PCT/US2009/055564 patent/WO2010025469A1/en active Application Filing
- 2009-08-31 KR KR1020117006827A patent/KR101813017B1/ko active IP Right Grant
-
2011
- 2011-02-28 CL CL2011000445A patent/CL2011000445A1/es unknown
- 2011-02-28 CO CO11024243A patent/CO6331444A2/es not_active Application Discontinuation
-
2014
- 2014-04-11 US US14/250,436 patent/US9517259B2/en active Active
- 2014-09-26 JP JP2014197235A patent/JP2015028058A/ja active Pending
-
2015
- 2015-06-22 CL CL2015001803A patent/CL2015001803A1/es unknown
-
2016
- 2016-11-08 US US15/346,198 patent/US9962435B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2334327B1 (en) | 2016-01-06 |
KR20110069024A (ko) | 2011-06-22 |
US9517259B2 (en) | 2016-12-13 |
US8821889B2 (en) | 2014-09-02 |
BRPI0918897B1 (pt) | 2021-06-15 |
CA2735164C (en) | 2021-08-31 |
US20170049877A1 (en) | 2017-02-23 |
EP2334327A1 (en) | 2011-06-22 |
SG193821A1 (en) | 2013-10-30 |
US9962435B2 (en) | 2018-05-08 |
JP2015028058A (ja) | 2015-02-12 |
JP2012501350A (ja) | 2012-01-19 |
AU2009287449A1 (en) | 2010-03-04 |
AU2009287449B2 (en) | 2015-04-30 |
US20140328877A1 (en) | 2014-11-06 |
NZ591188A (en) | 2012-12-21 |
CL2011000445A1 (es) | 2011-07-08 |
NZ603854A (en) | 2015-03-27 |
MX2011002071A (es) | 2011-04-05 |
JP5713454B2 (ja) | 2015-05-07 |
BRPI0918897A2 (pt) | 2015-12-01 |
CO6331444A2 (es) | 2011-10-20 |
CA2735164A1 (en) | 2010-03-04 |
US20110159033A1 (en) | 2011-06-30 |
CN102348466A (zh) | 2012-02-08 |
CN102348466B (zh) | 2014-05-07 |
WO2010025469A1 (en) | 2010-03-04 |
KR101813017B1 (ko) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015001803A1 (es) | Composición inmunogénica que comprende cepas del virus del oeste del nilo muerto o inactivado o cualquier antígeno del mismo; y método para disminuir síntomas clínicos asociados a infección por dicho virus en animales (div. sol. n° 445-11) | |
BRPI0923448A2 (pt) | vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina. | |
CL2014002415A1 (es) | Composición inmunogénica que permite aumentar una respuesta inmunitaria a un patógeno, particularmente viral, que comprende una glicoproteína antigénica del patógeno, donde la glicoproteina está parcialmente glicosilada en al menos un sitio de glicosilación; y vacuna útil para inmunizar un mamífero (div. sol. n° 2354-11). | |
BRPI0813307A2 (pt) | Composição imunogênica, vacina, e, processo para fabricar a vacina | |
BRPI0905725A2 (pt) | vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo | |
CL2014002676A1 (es) | Composicion inmunogenica trivalente que comprende mycoplasma hyopneumaniae (m. hyo), un antigeno del circovirus de tipo 2 (pcv2) y un antigeno del virus respiratorio y reproductivo porcino (srrp); procedimiento para inmunizar; procedimiento de preparacion de la composicion. | |
CL2011001993A1 (es) | Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto. | |
BR112012008060A2 (pt) | vetores baseados em adenovírus | |
BRPI0815662A2 (pt) | vacinas, antígenos, composições, e métodos profilácticos e terapêuticos para gripe | |
CL2012003299A1 (es) | Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma. | |
BRPI0814899A2 (pt) | Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo" | |
CR11812A (es) | Vacuna de vesicula, de membrana externa nativa multivalente del meningococo, metodo para su fabricacion y uso | |
CL2014002675A1 (es) | Composicion inmunogenica multivalente que comprende mycoplasma hyopneumaniae (m . hyo) y un antigeno del circovirus porcino del tipo 2 (pcv2); procedimiento para inmunizar; procedimiento para preparar la composicion. | |
CL2012002416A1 (es) | Proteina de union capaz de unirse a dll4; construccion de anticuerpo que comprende dicha proteina; conjugado de anticuerpo; acido nucleico, vector y celula huesped que comprenden el anticuerpo; composicion para la liberacion de una proteina de union; metodo para reducir la actividad del dll4 humano. | |
BRPI0923341B8 (pt) | oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso | |
CL2011002968A1 (es) | Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion. | |
BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
BR112012005349A2 (pt) | composição imunogênica, seu método de fabricação, método de fabricação de uma composição de vacina de matriz de proteína, e uso | |
BRPI0818354A2 (pt) | vacina preventiva do hiv baseada em anticorpos específicos para o hiv | |
CO6761399A2 (es) | Composiciones y métodos de vacuna del virus tipo 1b de diarrea viral bovina | |
BR112012030616A2 (pt) | concentração de antígenos de vacina com liofilização. | |
BRPI0808037A2 (pt) | Preparação liofilizada contendo vacina contra gripe e método para preparação da mesma. | |
CL2012002016A1 (es) | Vector para vacunas que comprende un polipeptido antigénico y un polipéptido hmgb1 o un fragmento funcional; composición que comprende el vector; método para potenciar respuesta inmune en un sujeto. | |
CL2015001562A1 (es) | Método para obtener una vacuna de mycoplasma. | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo |